Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Business Update
Company announces development program milestones for fiscal-year 2005
February 17th, 2005
DURECT Corp. (DRRX) announced its intended clinical and corporate milestones for the fiscal-year 2005. "These announced milestones are intended to assist the investment community to track our progress throughout the coming year," said James E. Brown, president and CEO of DURECT. "DURECT will continue to drive forward our development programs in 2005 to build lasting value for our shareholders." Its transdermal sufentanil product candidate is intended to provide extended chronic pain relief for up to 7 days, compared to 3 days of relief provided by currently available opiate patches. The company intends to complete phase I clinical studies and...
Source: Women's Health Weekly (2005-02-17)
|
